Physician profile
John P Wagner
NPI 1104869080
$8,443.80
in general payments reported to CMS, 2019-2025
56 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $520 · 2021: $874 · 2022: $1,202 · 2023: $1,527 · 2024: $1,762 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,179.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,229.40 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $901.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $658.32 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $622.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $403.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $349.77 | 2019-2025 | |
| Astellas Pharma US INC | $332.30 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $317.83 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $253.72 | 2019-2022 | |
| Femselect INC. | $237.81 | 2025 | Enplace |
| Lundbeck LLC | $232.95 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $211.24 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.58 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $174.00 | 2023-2025 | Rexulti |
| Tg Therapeutics, INC. | $149.98 | 2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.